ENPP2 and metabolic dysfunction-associated steatotic liver disease: Pharmacological studies with chemical inhibitors that inhibit ATX activity and LPA signaling in the liver of NAFLD animal models show an effect only on liver fibrosis and not on liver steatosis [241], although a genetic confirmation of this effect is still lacking.